Small-molecule activation of NAMPT as a potential neuroprotective strategy

References

[1] Lautrup S, Sinclair DA, Mattson MP, et al. NAD(+) in brain aging and neurodegenerative disorders. Cell Metab 2019;30:630–55.

[2] Coleman MP, Conforti L, Buckmaster EA, et al. An 85-kb tandem triplication in the slow Wallerian degeneration (Wlds) mouse. Proc Natl Acad Sci USA 1998;95:9985–90.

[3] Osterloh JM, Yang J, Rooney TM, et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 2012;337:481–4.

[4] Gerdts J, Brace EJ, Sasaki Y, et al. SARM1 activation triggers axon degeneration locally via NAD(+) destruction. Science 2015;348:453–7.

[5] Pieper AA, McKnight SL, Ready JM. P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chem Soc Rev 2014;43: 6716–26.

[6] Wang G, Han T, Nijhawan D, et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 2014;158:1324–34.

[7] Katsyuba E, Romani M, Hofer D, et al. NAD(+) homeostasis in health and disease. Nat Metab 2020;2:9–31.

[8] Covarrubias AJ, Perrone R, Grozio A, et al. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol 2021;22:119–41.

[9] Yao H, Liu M, Wang L, et al. Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and their preclinical neuroprotective activity. Cell Res 2022;32: 570–84.

[10] Wang L, Liu M, Zu Y, et al. Optimization of NAMPT activators to achieve in vivo neuroprotective efficacy. Eur J Med Chem 2022;236:114260.

RIGHTS & PERMISSIONS

The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.